RxDoctor Payments Data

Michael Bank, MD

Internal Medicine · New Orleans, LANPI 1932736402

Payments from drug & device makers

$522in general payments, 2019–2025

Across 18 payments — averaging $28.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$122
  • Lilly USA, LLC$110
  • AbbVie$57
  • Exact Sciences$47
  • Takeda Pharmaceuticals U.S.A., Inc.$34
  • Pfizer$33
  • plus $119 from 6 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 50th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$17,561
Medicare patients
117
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin46$66,875
OzempicSemaglutide44$51,828
MounjaroTirzepatide26$33,353
EliquisApixaban35$32,011
TrulicityDulaglutide17$27,935
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$13,515
TradjentaLinagliptin14$9,591
Valsartan72$2,024
Nifedipine ErNifedipine78$1,668
Atorvastatin Calcium182$1,412
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,381
Albuterol Sulfate HfaAlbuterol Sulfate27$1,025
Rosuvastatin Calcium117$795
Losartan Potassium94$759
Gabapentin53$635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$110$61,28843 claims
Novo NordiskOzempic$19$51,82844 claims
PfizerEliquis$33$32,01135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →